Clinical Trials Logo

Hemophilia A With Inhibitor clinical trials

View clinical trials related to Hemophilia A With Inhibitor.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04548791 Terminated - Clinical trials for Hemophilia A With Inhibitor

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

Start date: May 17, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the trial is to evaluate the PK, bioavailability, PD, efficacy and safety of MarzAA for on demand treatment and control of bleeding episodes in adult subjects with inherited bleeding disorders.

NCT ID: NCT04489537 Terminated - Clinical trials for Hemophilia A With Inhibitor

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

Start date: May 4, 2021
Phase: Phase 3
Study type: Interventional

The purpose of the trial is to evaluate the safety and efficacy of MarzAA for on-demand treatment and control of bleeding episodes in hemophilia A or B patients with inhibitors compared with their standard of care (SOC).

NCT ID: NCT04303572 Terminated - Clinical trials for Hemophilia A With Inhibitor

The Hemophilia Inhibitor Eradication Trial

Start date: November 1, 2021
Phase: Phase 3
Study type: Interventional

This is a multi-center randomized phase III clinical trial, the Inhibitor Eradication Trial, in which Eloctate ITI plus Emicizumab will be compared with Eloctate ITI alone to eradicate inhibitors in severe hemophilia A.

NCT ID: NCT03204539 Terminated - Hemophilia A Clinical Trials

INdividualized ITI Based on Fviii(ATE) Protection by VWF

INITIATE
Start date: June 1, 2017
Phase: Phase 4
Study type: Interventional

The primary goal of the INITIATE trial is to compare the clinical outcome of individualized lot selection to random lot selection utilizing one plasma-derived von Willebrand factor (VWF)/coagulation factor (FVIII) complex concentrate for immune tolerance induction (ITI) in subjects with congenital Hemophilia A, FVIII activity ≤2%, and a historical high-titer inhibitor [≥5 Bethesda Unit (BU)].